ASONGTIA NTONGHAWAH: Open Payments
NPI 1811343338 · LANHAM, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 22 payments from 7 companies in 2025. Trend: 2023 $1,002 · 2024 $2,294 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 9 | $193 |
| ACADIA Pharmaceuticals Inc | 2 | $101 |
| Neuronetics, Inc. | 3 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 2 | $62 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| MERZ NORTH AMERICA, INC. | 1 | $19 |
Products named: REXULTI, NUPLAZID, NEUROSTAR TMS THERAPY SYSTEM, CAPLYTA, ABILIFY MAINTENA, Qelbree, ABILIFY ASIMTUFII, Xeomin.
Industry payments across MD — which companies pay providers there.
